- The Prohuman
- Posts
- Cancer drug built by AI?
Cancer drug built by AI?
Plus: Learn how to build AI agents and automate 80% of your work (only 50 can join)
Welcome, Prohumans.
Here’s what you’re going to explore in this post:
AI-designed cancer drug moves to human trials
LangChain eyes unicorn status with new funding round
Replit expands to Azure, joins Microsoft’s enterprise cloud
Just happened in AI
Giveaway by Aircampus:
No Code. No Overwhelm. Just Drag, Drop, Deploy
On 11th July at 10AM EST, join a 3-hour Masterclass where you’ll learn how to build AI Agents that automate your daily work — no coding needed.
You’ll create agents that reply to emails, follow up with leads, manage tasks, and run your workflows — quietly, efficiently, and around the clock.
We’ll walk you through it step by step, using simple tools like n8n, Make.com, and Relevance AI.
If you're a founder, creator, or solo operator — this is how you scale without hiring.
Google’s AI just helped create a cancer drug, trials begin soon

Isomorphic Labs, an Alphabet subsidiary, is starting human trials on a cancer drug developed with DeepMind’s AlphaFold 3 AI.
Here’s everything you need to know:
The drug targets cancer using AI-generated insights into protein structures.
AlphaFold 3 predicts how proteins behave, helping design more effective treatments.
This marks a rare leap: from AI simulation to actual clinical use.
WHO data shows nearly 10 million cancer deaths in 2022, demand for new drugs is urgent.
Isomorphic Labs raised $600M to fund the trials and future drug design.
Partnerships with pharma giants like Novartis and Eli Lilly total $3B+.
Competitors like Novo Nordisk and Anima Biotech are also investing heavily in AI drug discovery.
AI’s promise in healthcare isn’t just about diagnostics or chatbots. It’s in discovery, solving problems humans couldn’t brute-force through before. If these trials succeed, it’s not just a win for cancer patients, it’s a proof point for what AI can build when it's focused on science, not clicks.
LangChain’s next move? $1B valuation

LangChain, once an open source darling of AI developers, is reportedly raising a fresh round at a near-unicorn valuation.
Here’s everything you need to know:
The round is led by IVP and could push LangChain’s value to around $1 billion.
LangChain launched in late 2022 to make LLMs more useful with tools for app-building.
Its GitHub repo quickly exploded: 111K stars and 18,000+ forks.
But as LLM providers caught up, LangChain had to evolve.
Enter LangSmith: a closed-source monitoring tool for LLM apps that’s become its revenue engine.
LangSmith now brings in $12M–$16M in annual recurring revenue.
Customers include Klarna, Rippling, and Replit with pricing starting free and scaling up.
LangChain’s rise shows that open-source buzz isn’t enough. You need staying power. By pivoting to LangSmith, they’ve found product-market fit in a fast moving space and may just become the first unicorn built on LLM ops.
Replit partners with Microsoft, Google Cloud takes a hit

Replit just struck a strategic deal with Microsoft that reshapes how its no-code platform reaches enterprise teams.
Here’s everything you need to know:
Replit will now be available via the Azure Marketplace, simplifying procurement for Microsoft clients.
The integration links Replit apps to Microsoft’s cloud stack: containers, VMs, and Neon Serverless Postgres.
Azure will share in revenue from Replit-powered production apps.
Replit and GitHub Copilot don’t directly compete, they target different user bases and workflows.
This move positions Replit as a Figma for apps: aimed at teams building internal tools with little code.
CEO Amjad Masad revealed Replit jumped from $10M to $100M ARR in just six months.
While not exclusive, the deal shifts momentum from Google Cloud, where Replit apps are typically hosted.
Replit is playing a clever game, partnering without picking sides. By embedding into Microsoft’s ecosystem while staying on Google Cloud, it’s quietly turning into the Switzerland of cloud-based app prototyping. And with $100M ARR and enterprise distribution, it might just become indispensable.

Thanks for reading…
That’s a wrap.
What's on your mind?
Share your best ideas with us at theprohumanai@gmail. com
We'll bring your ideas to life. Send them our way, and we'll get to work on making them a reality.
Did you find value in our newsletter today?Your feedback can help us create better content for you! |
![]() | I hope this was useful… If you want to learn more then visit this website. Get your brand, product, or service in front of 700,000+ professionals here. Follow us on 𝕏/Twitter to learn more about AI: |